Metformin Use and Stroke Risk in Hispanic and Non-Hispanic Diabetic Male Veterans

Disclosure:
Dr. Vasquez has nothing to disclose.

Headache Clinical Trials II

Start Time

Pub.

Title

Presenter

11:30 AM

001

Impact of Fremanezumab on Response Rates, Acute Medication Use, and Disability in Patients With Episodic Migraine Who Have Failed at Least One Prior Migraine Preventive Medication

Disclosure:
Dr. Winner has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan, Amgen, Supernus, Teva, Novartis, Avanir, and Promius.

Behavioral Issues

Start Time

Pub.

Title

Presenter

11:30 AM

001

Incidence and trends of Frontotemporal Disorders in Olmsted County: a population based study (1995-2010).

Continuous Objective Monitoring in Parkinson’s Disease: A description of over 25,000 Parkinson’s symptom scores across the world using the Personal KinetiGraph (PKG) wearable monitoring device

Disclosure:
Dr. Lynch has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with GKC. Dr. Lynch holds stock and/or stock options in GKC which sponsored research in which Dr. Lynch was involved as an investigator. Dr. Lynch holds stock and/or stock options in GKC. Dr. Lynch has received research support from GKC.

Research Methodology and Education: Graduate Education

Start Time

Pub.

Title

Presenter

11:30 AM

003

Application of Non-Mydriatic Retinal Photography in the Outpatient Neurology Setting

Disclosure:
Dr. Pyatka has nothing to disclose.

Cerebrovascular Disease and Interventional Neurology ePoster Session

Start Time

Pub.

Title

Presenter

11:30 AM

004

Atypical presentation of Neurologic complications of Osler-Weber-Rendu Syndrome: A case series

Disclosure:
Dr. Saleh Velez has nothing to disclose.

Headache Clinical Trials II

Start Time

Pub.

Title

Presenter

11:30 AM

004

ACT for Migraine: Effect of Acceptance and Commitment Therapy (ACT) for High Frequency Episodic Migraine without Aura: A phase-II, multicentric, randomized, open-label study

Disclosure:
Dr. Grazzi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan, Inc. and ElectroCore, LLC.

Behavioral Issues

Start Time

Pub.

Title

Presenter

11:30 AM

004

The Cognitive Aspects of Sexual Intimacy in Dementia Patients: A Neurophysiological Review and Insights for Diagnosis and Treatment

Disclosure:
Dr. Nordvig has nothing to disclose.

Autoimmune and Paraneoplastic Encephalitis

Start Time

Pub.

Title

Presenter

11:30 AM

004

Determining the Prevalence of Sleep Disturbances in Autoimmune Encephalitis

Trends In Outpatient And Hospitalization Charges Relevant To the Management of Chronic Inflammatory Demyelinating Polyneuropathy: A Statewide Planning and Research Cooperative System (SPARCS) Study 2002-2014

Disclosure:
Dr. Zhang has nothing to disclose.

Epilepsy: Women's Issues

Start Time

Pub.

Title

Presenter

11:30 AM

004

Is Pre-conceptional counselling for Women with Epilepsy (WWE) beneficial: Experience from Kerala Registry of Pregnancy and Epilepsy, India

Disclosure:
Dr. BAISHYA has nothing to disclose.

The Power of Case Reporting in Neuro-Oncology I

Start Time

Pub.

Title

Presenter

11:30 AM

004

Leptomeningeal Carcinomatosis in a patient with Waldenstrom Macroglobulinemia.

Eptinezumab Meaningfully Improves Quality of Life (QoL) in Patients with Episodic or Chronic Migraine Within 1 Month After Treatment

Disclosure:
Dr. Spierings has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Amgen. Dr. Spierings has received research support from Amgen, Teva, Alder, AOBiome, Allergan, and Pfizer.

Disclosure:
Dr. Beversdorf has received personal compensation for consulting serving on a scientific advisory board, speaking or other activities with Best Doctors ,YAMO pharmaceuticals, Quadrant Biosciences. Dr. Beversdorf has received personal compensation in an editorial capacity for Research in Autism Spectrum Disorders.

Autoimmune and Paraneoplastic Encephalitis

Start Time

Pub.

Title

Presenter

11:30 AM

007

Imaging and Pathologic Findings in an Adult and Pediatric Case of Anti-GABA-A Receptor Encephalitis

A case of prosopagnosia with the retained ability to recognize caricatures

Disclosure:
Dr. Cook has nothing to disclose.

Headache Clinical Trials II

Start Time

Pub.

Title

Presenter

11:30 AM

009

Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine

Disclosure:
Dr. Ailani has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alder, Amgen, Allergan, Electrocore, Eli, Lilly and Company, Promius, Teva, Impel, Satsuma, Miller, Communications, Avent, Alpha, Sites Consulting. Dr. Ailani has received personal compensation in an editorial capacity for Current Pain and Headache Reports and Unusual Headache Syndromes. Dr. Ailani has received research support from American Migraine Foundation ARMR, Biohaven, Allergan.

Behavioral Issues

Start Time

Pub.

Title

Presenter

11:30 AM

009

Allopregnanolone improves neuropsychiatric symptoms in elderly men with Fragile X-associated tremor/ataxia syndrome (FXTAS): Results from an open label study

Disclosure:
Dr. Trivedi has nothing to disclose.

Autoimmune and Paraneoplastic Encephalitis

Start Time

Pub.

Title

Presenter

11:30 AM

009

Improving Utilization of Neurological Autoantibody Testing at a Public Hospital: A Quality Improvement Project

Disclosure:
Dr. Blackburn has nothing to disclose.

Stroke in the Young and Elderly

Start Time

Pub.

Title

Presenter

11:30 AM

009

Hypercoagulable States in Young Adults with Ischemic Stroke in a Stroke Belt State

One-Year Treatment with Galcanezumab in Patients with Chronic Migraine: Results from the Open-Label Phase of the REGAIN Study

Disclosure:
Dr. Detke has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Eli Lilly and Company. Dr. Detke holds stock and/or stock options in Eli Lilly and Company which sponsored research in which Dr. Detke was involved as an investigator.

OnabotulinumtoxinA Is Safe and Effective in Patients Who Discontinue Topiramate: Results of the FORWARD Study

Disclosure:
Dr. Rothrock has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan, Amgen, Lilly, and Supernus. Dr. Rothrock has received research support from Allergan plc, Amgen, and Dr. Reddy’s Laboratories.

Clinical Experience in Over 100 Using Pimavanserin for Parkinson’s Disease Psychosis

Disclosure:
Dr. Harsh has nothing to disclose.

Research Methodology and Education: Graduate Education

Start Time

Pub.

Title

Presenter

11:30 AM

020

Effect on the Clinical Learning Environment after Expansion of the Thrombectomy Time Window

Disclosure:
Dr. Aradine has nothing to disclose.

Headache Clinical Trials II

Start Time

Pub.

Title

Presenter

11:30 AM

021

Effect of Age on Efficacy and Safety of Galcanezumab Treatment in Adult Patients with Migraine

Disclosure:
Dr. Stauffer has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Eli Lilly and Company. Dr. Stauffer holds stock and/or stock options in Eli Lilly and Company as minor stockholder.

The Effect of High-Intensity Exercise on Objective Sleep Outcomes in Parkinson’s Disease

Disclosure:
Dr. Amara has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Jazz Pharmaceuticals and Grey Matter Technologies. Dr. Amara has received research support from Parkinson's Disease Foundation and serves as site investigator for studies sponsored by the Michael J. Fox Foundation for Parkinson's Research, Abbvie, Axovant Neurological Solutions, and Jazz Pharmaceuticals.

Multiple, Once-Daily, Oral Doses of 150 mg Ubrogepant Administered for 28 Days Are Generally Well Tolerated, With No Clinically Significant Elevation of Alanine Aminotransferase in Healthy Adult Males

Disclosure:
Dr. Ankrom has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck & Co, Inc.. Dr. Ankrom holds stock and/or stock options in Merck & Co, Inc., which sponsored research in which Dr. Ankrom was involved as an investigator.

Cognitive Disorders

Start Time

Pub.

Title

Presenter

11:30 AM

024

CSF1R Mutation-negative Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP): Genotypic Heterogeneity in an Important Cause of Early-onset Dementia

Disclosure:
Dr. Trewin has nothing to disclose.

Autoimmune and Paraneoplastic Encephalitis

Start Time

Pub.

Title

Presenter

11:30 AM

024

Evaluation of the Malignancy Risk Associated With Paraneoplastic Antibodies

Disclosure:
Dr. Wong has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Advance Medical, Merck, and Novocure. Dr. Wong has received research support from Novocure.

Parkinson's Disease Non-Motor Symptoms

Start Time

Pub.

Title

Presenter

11:30 AM

029

Impulse Control Disorders in Parkinson’s disease – a cross-sectional and longitudinal study of severity

Disclosure:
Dr. Baig has nothing to disclose.

Research Methodology and Education: Undergraduate Education

Start Time

Pub.

Title

Presenter

11:30 AM

029

The Effects of Residents’ teaching on Medical Students’ Neurology Experience and Interest

Disclosure:
Dr. Keser has nothing to disclose.

Aging and Dementia: Neuropsychology and Clinical Studies I

Start Time

Pub.

Title

Presenter

11:30 AM

030

Cognitive Profiles in Amyloid-Positive Mild Cognitive Impairment and Alzheimer’s Disease with and without Tau

Student Satisfaction and NBME Outcomes with Team Based Learning on the Neurology Clerkship, a Pilot Study

Disclosure:
Dr. Dunham has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen and Genzyme. Dr. Dunham has received research support from Biogen.

You Never Forget Your First? Impact of Interview Timing on Final Rank Order

Disclosure:
Dr. Schloemer has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with SERMO (private social media network for physicians) .

Disclosure:
Dr. Bove has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Roche Genentech, Novartis, EMD Serono, Biogen, Sanofi Genzyme, and Pear Digital. Dr. Bove has received research support from Akili Interactive.

Parkinson's Disease Non-Motor Symptoms

Start Time

Pub.

Title

Presenter

11:30 AM

045

Profile of Non-motor Symptoms and Impact on Quality of Life of Parkinson Disease Patients in a Neurology Clinic in Lagos Nigeria

Disclosure:
Dr. Chenna has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Monogram Biosciences, Laboratory Corporation of America.

Disclosure:
Dr. Farbman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Dr. Farbman has received honoraria for advisory board participation from Teva Pharmaceuticals and UCB.

Neuro Trauma and Sports Neurology I

Start Time

Pub.

Title

Presenter

11:30 AM

049

Chronic Neurobehavioral Symptoms in Retired Athletes and Military Veterans with a History of Head Trauma

Efficacy of ND0612 for nocturnal problems and early morning OFF: A blinded rater study of 2 dosing regimens

Disclosure:
Dr. Espay has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbvie, Neuroderm, TEVA, Impax, Acadia, Acorda, Sunovion, Lundbeck, Osmotica Pharmaceutical, and USWorldMeds. Dr. Espay has received research support from Great Lakes Neurotechnologies and Michael J Fox Foundation.

Neuro Trauma and Sports Neurology I

Start Time

Pub.

Title

Presenter

11:30 AM

053

MULES on the Sidelines: A Vision-Based Assessment Tool for Sports-Related Concussion

Disclosure:
Dr. Bigaud has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis Pharma AG, Basel, Switzerland..

Dissection and Vasculopathy

Start Time

Pub.

Title

Presenter

11:30 AM

066

Clinicoradiographic Course of Focal Intracranial Arteriopathy in Young Adults

Disclosure:
Dr. MacLellan has nothing to disclose.

The Extremes of Extremity and Back Pain

Start Time

Pub.

Title

Presenter

11:30 AM

066

High Frequency Spinal Cord Stimulation (HF-SCS) at 10 kHz for the Treatment of Neuropathic Limb Pain from Painful Diabetic Neuropathy

Disclosure:
Dr. Argoff has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Needs to be Completed . Dr. Argoff has received personal compensation in an editorial capacity for Needs to be completed. Dr. Argoff has received research support from Needs to be completed.

Neurocritical Care: Cardiac Arrest

Start Time

Pub.

Title

Presenter

11:30 AM

066

Evidence of Late Cognitive Recovery after Cardiac Arrest with Anoxia and Extended Coma

CONVEY, A Phase 2 Placebo-Controlled, Double-Blind, Enriched Enrollment Randomized Withdrawal Study Design of Vixotrigine for the Treatment of Pain in Participants With Confirmed Small Fiber Neuropathy

Disclosure:
Dr. Shinobu has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities as an employee of Biogen and on the Scientific Advisory Board for Inscopix Inc. Former employee of Decibel Therapeutics and Voyager Therapeutics. Dr. Shinobu holds stock and/or stock options in Decibel Therapeutics which sponsored research in which Dr. Shinobu was involved as an investigator.

Disclosure:
Dr. Bar-Or has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with speaker/consulting fees/grant support from Atara Biotherapeutics, Biogen, Celgene/Receptos, Genentech/Roche, GlaxoSmithKline, MedImmune, Merck/EMD Serono, Novartis and Sanofi-Genzyme. Dr. Bar-Or has received research support from grant support from Atara Biotherapeutics, Biogen, Celgene/Receptos, Genentech/Roche, GlaxoSmithKline, MedImmune, Merck/EMD Serono, Novartis and Sanofi-Genzyme.

Dissection and Vasculopathy

Start Time

Pub.

Title

Presenter

11:30 AM

069

Moyamoya Disease and Associated Risk Factors: Analysis of a National Database

Disclosure:
Dr. Gupta has nothing to disclose.

The Extremes of Extremity and Back Pain

Start Time

Pub.

Title

Presenter

11:30 AM

069

Electrical Impedance Myography for Assessing Patients with Low Back Pain

Disclosure:
Dr. Rutkove has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Myolex, Biogen, Axcella Health, Merck. Dr. Rutkove has received personal compensation in an editorial capacity for Annals of Neurology. Dr. Rutkove has received compensation for serving on the Board of Directors of Myolex, Inc. Dr. Rutkove holds stock and/or stock options in Myolex, Inc.

Disclosure:
Dr. Allen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with CSL Behring, Biotest. Dr. Allen has received research support from CSL Behring.

11:30 AM

105

Does CIDP Increase The Risk of Acquiring Other Autoimmune Disorders? A New York State Planning and Research Cooperation System Database Analysis (1998-2014)

Disclosure:
Dr. Islam has nothing to disclose.

11:30 AM

106

First Report of Confirmed CIDP in a Patient with Neuromyelitis Optica Spectrum Disorder (NMOSD)